TuisNVAX • NASDAQ
add
Novavax Inc
Vorige sluiting
$7,75
Dagwisseling
$7,84 - $8,81
Jaarwisseling
$5,01 - $10,64
Markkapitalisasie
1,41 mjd USD
Gemiddelde volume
3,21 m
P/V-verhouding
4,82
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 70,44 m | -16,64% |
Bedryfskoste | 46,12 m | -42,92% |
Netto inkomste | -202,38 m | -66,84% |
Netto winsgrens | -287,29 | -100,16% |
Wins per aandeel | -1,25 | -64,47% |
EBITDA | -72,80 m | 37,84% |
Effektiewe belastingkoers | 0,32% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 762,89 m | -16,12% |
Totale bates | 1,18 mjd | -31,10% |
Totale aanspreeklikheid | 1,34 mjd | -40,30% |
Totale ekwiteit | -156,67 m | — |
Uitstaande aandele | 162,50 m | — |
Prys om te bespreek | -8,07 | — |
Opbrengs op bates | -15,77% | — |
Opbrengs op kapitaal | -110,07% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -202,38 m | -66,84% |
Kontant van bedrywe | 107,80 m | 174,44% |
Kontant van beleggings | -136,53 m | -527,83% |
Kontant van finansiering | 42,44 m | 43 854,64% |
Netto kontantverandering | 14,38 m | 113,44% |
Beskikbare kontantvloei | 96,84 m | 223,39% |
Meer oor
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company's developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company is also developing vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax also develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
Gestig
1987
Webwerf
Werknemers
952
